MENU

ARVN Arvinas Forecast, Technical & Fundamental Analysis

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins... Show more

Industry: #Biotechnology
A.I.Advisor
Nov 17, 2026

Arvinas (ARVN) Stock Forecast: Post-Approval Pipeline Puts Next-Generation Protein Degraders in Focus

Key Takeaways

  • Near-term catalyst: Early monotherapy data from the ARV-393 BCL6 degrader program, expected in the fourth quarter of 2026, is a key clinical readout that could validate Arvinas' expansion beyond breast cancer.
  • Neurodegeneration optionality: ARV-102, a brain-penetrant LRRK2 (leucine-rich repeat kinase 2) degrader, is advancing toward a planned Phase 1b trial in progressive supranuclear palsy (PSP), a potential inflection point for the pipeline's breadth.
  • Financial runway: A cash balance of roughly $685 million at the end of 2025, plus non-dilutive funding from Pfizer and Novartis partnerships, is expected to fund operations into the second half of 2028.
  • Strategic repositioning: The out-licensing of VEPPANU (vepdegestrant) to Rigel Pharmaceuticals refocuses Arvinas on earlier-stage, platform-defining programs rather than commercial execution.
  • Analyst sentiment: Consensus ratings skew toward Buy with a widely dispersed average price target near $14, reflecting both enthusiasm for the PROTAC platform and caution about clinical and competitive risk.
  • Macro sensitivity: As a pre-profit biotech, Arvinas remains sensitive to interest rates and biotech funding conditions, which shape the cost and availability of future capital.
  • For additional context on this name, explore Major News, Today's Price Move, Price Targets, and Earnings on Tickeron's dedicated pages.
  • Readers can also explore Trending AI Robots for additional AI-driven market insights.

Strategic Positioning and Competitive Outlook

Arvinas is a clinical-stage biopharmaceutical company that pioneered PROTAC (PROteolysis TArgeting Chimera) protein degraders, a modality designed to tag and remove disease-causing proteins rather than merely inhibiting them. The company's medium-term positioning rests on translating this platform into validated clinical programs across oncology, neurodegenerative, and neuromuscular disease.

The strategic picture changed meaningfully in 2026. Following the U.S. Food and Drug Administration (FDA) approval of VEPPANU — the first-ever approved PROTAC therapy — in May 2026, Arvinas and partner Pfizer out-licensed the drug to Rigel Pharmaceuticals. That decision signals a deliberate pivot away from commercial-scale oncology execution and toward earlier-stage, higher-optionality assets where Arvinas believes its platform offers the greatest differentiation.

Structurally, the company now leans on a diversified preclinical and clinical pipeline: ARV-393 targeting BCL6 (B-cell lymphoma 6) in lymphoma, ARV-806 targeting KRAS G12D mutations (a common driver across pancreatic, colorectal, and lung cancers), ARV-102 for neurodegenerative disease, and ARV-027 for SBMA (spinal and bulbar muscular atrophy). This breadth is a competitive advantage, but it also concentrates risk in unproven programs whose clinical value has yet to be established.

Major Catalysts Ahead

Several data and regulatory events could reshape investor expectations in the coming quarters. The most immediate is fourth-quarter 2026 monotherapy data from ARV-393, with an early focus on T-cell lymphomas. Updated B- and T-cell lymphoma data, including combination results, are expected in mid-2027.

In neurodegeneration, ARV-102 has shown median reductions of roughly 50% or greater in cerebrospinal fluid LRRK2 in Parkinson's disease patients, a biomarker signal that supports further development. A Phase 1b trial in PSP is planned for 2027 pending regulatory feedback, and initial Phase 1 data for ARV-027 are expected around mid-2027. The ARV-6723 program, an HPK1 (hematopoietic progenitor kinase 1) degrader, is expected to generate initial clinical data in the second half of 2027.

Analyst rating trends reflect a cautiously optimistic, but sharply divided, outlook. Citigroup upgraded Arvinas to Buy in January 2026 and has since raised its price target to $24, while Piper Sandler, Barclays, and Evercore ISI have published targets in the $18 to $20 range. By contrast, Goldman Sachs downgraded the stock to Sell with a $6 target in late 2025, and Wells Fargo moved to Hold in August 2026. The consensus 12-month price target sits near $14, implying meaningful upside from recent levels but with an unusually wide spread that underscores genuine uncertainty.

Industry and Macroeconomic Forces

Arvinas operates at the intersection of targeted protein degradation — a rapidly maturing drug class — and broader biotechnology financing conditions. The FDA approval of VEPPANU validates the PROTAC modality at a regulatory level, which could lower perceived platform risk for the entire field and attract partnership capital. At the same time, the narrower-than-expected clinical benefit seen in the broader breast cancer population highlights the execution risk inherent in translating platform science into differentiated products.

Macro forces matter directly. As a pre-profit company, Arvinas' access to non-dilutive partnerships and future equity raises is influenced by interest rates and overall risk appetite in biotech. A higher cost of capital can compress valuations for long-duration, pre-revenue assets, while a more accommodable funding environment tends to expand the premium investors are willing to pay for pipeline optionality. Inflation in clinical trial costs and competitive pressure from rival protein degraders and oral SERDs (selective estrogen receptor degraders) also shape the company's operating trajectory.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF (exchange-traded fund), or other asset may move bullish, bearish, or sideways over the next week or month. The tool is built to identify developing trends, evaluate possible breakouts or reversals, and surface predictions across a broad universe of tradable instruments. It includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking names like Arvinas, exploring the Trend Prediction Engine can add a data-driven layer to forward-looking analysis.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Arvinas' trajectory will be defined by whether its next wave of degraders can generate clinically meaningful data across multiple disease areas. The company's cost structure has been streamlined through restructuring, and its extended cash runway into 2028 reduces near-term financing risk while it awaits key readouts.

Longer-term themes include the company's ability to expand its market opportunity beyond the ESR1-mutated breast cancer niche, the durability of margins as programs mature, and the competitive landscape in KRAS-targeted oncology, where rivals such as Revolution Medicines are advancing rapidly. Regulatory developments — including potential FDA guidance on blood-brain-barrier-penetrant degraders — could either accelerate or slow the neurodegeneration programs.

Capital allocation will remain a central focus, as Arvinas must balance continued investment in R&D (research and development) against the discipline of milestone-based, non-dilutive funding from partners. Consensus analyst expectations embed a wide range of outcomes, with some targets reflecting confidence in pipeline breadth and others discounting meaningful execution risk. The divergence itself is a signal that 2026 and 2027 data readouts, rather than any single event, will ultimately determine the stock's future outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARVN is expected to report earnings to rise 4.17% to -85 cents per share on March 01

Arvinas ARVN Stock Earnings Reports
Q4'26
Est.
$-0.85
Q3'26
Missed
by $0.02
Q2'26
Beat
by $2.96
Q1'26
Beat
by $0.03
Q4'25
Missed
by $0.59
The last earnings report on November 03 showed earnings per share of -81 cents, missing the estimate of -80 cents. With 594.06K shares outstanding, the current market capitalization sits at 419.13M.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
PROM.X5.6048330.078562
+1.42%
Prom cryptocurrency
MULTI.X0.020006N/A
N/A
Multichain cryptocurrency
MAV.X0.006889-0.000026
-0.37%
Maverick Protocol cryptocurrency
IOTX.X0.002477-0.000019
-0.77%
IoTeX cryptocurrency
DOGE.X0.058802-0.001229
-2.05%
Dogecoin cryptocurrency

ARVN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with BCYC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then BCYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+0.74%
BCYC - ARVN
47%
Loosely correlated
+0.63%
OLMA - ARVN
46%
Loosely correlated
-1.90%
AXON - ARVN
46%
Loosely correlated
-2.56%
VCYT - ARVN
46%
Loosely correlated
+0.92%
RIGL - ARVN
46%
Loosely correlated
-1.85%
More
A.I. Advisor
published General Information

General Information

a developer of therapies to degrade disease-causing proteins

Industry Biotechnology

Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
246
Web
https://www.arvinas.com
Arvinas (ARVN) Stock Forecast: Post-Approval Pipeline Puts Next-Generation Protein Degraders in Focus